CompletedPhase 1NCT02639117

Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas

Studying Gorlin syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Arizona
Principal Investigator: Mariette Marsh
University of Arizona Human Subjects Protection Program
Intervention: Vismodegib(drug)
Enrollment: 4 target
Eligibility: 18 years · All sexes
Timeline: 2015 – 2017

Study locations (1)

Arizona Cancer Center, Tucson, Arizona, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02639117 on ClinicalTrials.gov

Other trials for Gorlin syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT06050122
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.

See all trials for Gorlin syndrome →

← Back to all trials